MARKET

RHHBY

RHHBY

Roche Hldg
OTCQX
30.50
-0.74
-2.37%
Closed 15:59 04/24 EDT
OPEN
30.38
PREV CLOSE
31.24
HIGH
30.56
LOW
30.15
VOLUME
717.14K
TURNOVER
21.80M
52 WEEK HIGH
53.86
52 WEEK LOW
29.95
MARKET CAP
156.26B
P/E (TTM)
14.36
1D
5D
1M
3M
1Y
5Y
Hookipa to receive $10M from Roche as FDA clears cancer trial
Hookipa to receive $10M from Roche as FDA clears cancer trial. The company's cancer vaccine HB-700 targets the five most prevalent KRAS mutations in several tumor types. The U.S. FDA cleared its clinical development for a clinical study. Roche terminated its collaboration agreement with Hookipa in April.
Seeking Alpha · 17h ago
DZ BANK AG Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
TipRanks · 19h ago
GLOBAL MARKETS-Shares jump on tech boost; fragile yen on intervention watch
World stocks rise on Wednesday led by gains in the tech sector. Japan's yen touches 34-year low against the dollar and is on intervention watch. After-hours surge in shares of Tesla lifts sentiment in Asia and Europe. The euro rises to its highest in more than a week after strong euro zone PMIs.
Reuters · 20h ago
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
HOOKIPA Pharma Inc (NASDAQ:HOOK) received clearance from the FDA for its HB-700 application for KRAS-mutated cancers. In January, Roche terminated the collaboration and licensing agreement for HOOKIPa’s HB- 700 program in KRAS mutated cancers. The company will regain full control of the rights to the program in 2024.
Benzinga · 21h ago
Artisan International Fund Q1 2024 Commentary
Seeking Alpha · 21h ago
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
NASDAQ · 22h ago
UPDATE 1-Biogen beats quarterly profit estimates, Alzheimer's drug sales jump
Biogen beats quarterly profit estimates, Alzheimer's drug sales jump. The company's shares up 4% before the bell. Biogen has cut jobs and abandoned controversial drug Aduhelm to boost growth. Company says its new drug Leqembi recorded global sales of about $19 million.
Reuters · 1d ago
UBS Remains a Hold on Roche Holding AG (RHHVF)
TipRanks · 1d ago
More
About RHHBY
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

Webull offers Roche Holding AG (ADR) stock information, including OTCQX: RHHBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RHHBY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RHHBY stock methods without spending real money on the virtual paper trading platform.